Clinical Trial Update: Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease [Phase 2]

View source ↗

Summary

RP2 is being studied as an immunoprevention agent for high-risk oral precancerous disease in a Phase II trial that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-risk Oral Precancerous Disease

Drugs mentioned

• RP2

Snippet

Sponsor: Glenn J. Hanna | Conditions: High-Risk Oral Precancerous Disease | Phase 2 | Status: RECRUITING